Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Show full item record



Permalink

http://hdl.handle.net/10138/340331

Citation

Salminen , J K , Kuoppamäki , V , Talala , K , Taari , K , Mäkinen , J , Peltola , J , Tammela , T L J , Auvinen , A & Murtola , T J 2021 , ' Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer ' , International Journal of Cancer , vol. 149 , no. 2 , pp. 307-315 . https://doi.org/10.1002/ijc.33535

Title: Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
Author: Salminen, Jukka K.; Kuoppamäki, Viivu; Talala, Kirsi; Taari, Kimmo; Mäkinen, Jussi; Peltola, Jukka; Tammela, Teuvo L. J.; Auvinen, Anssi; Murtola, Teemu J.
Contributor organization: HUS Abdominal Center
Clinicum
Urologian yksikkö
Department of Surgery
Helsinki University Hospital Area
University of Helsinki
Date: 2021-07-15
Language: eng
Number of pages: 9
Belongs to series: International Journal of Cancer
ISSN: 0020-7136
DOI: https://doi.org/10.1002/ijc.33535
URI: http://hdl.handle.net/10138/340331
Abstract: Antiepileptic drugs (AEDs) with histone deacetylase (HDAC) inhibitor properties decrease prostate cancer (PCa) cell proliferation in vitro. A population-based cohort of 78 615 men was used to evaluate the risk of PCa among users of AEDs. Study population was linked to the Finnish national prescription database to obtain information on individual medication reimbursements in 1996 to 2015. Cox regression with antiepileptic medication use as a time-dependent variable was used to analyze PCa risk overall, and low, medium and high-risk PCa separately. The analysis was adjusted for age, screening trial arm, and other drugs in use, including statins, antidiabetic drugs, antihypertensive drugs, aspirin, and nonsteroidal anti-inflammatory drugs. Compared to the nonusers of AEDs, overall PCa risk was decreased among AED users (hazard ratio [HR] = 0.86, 95% confidence interval [CI] = 0.76-0.96). A similar PCa risk decrease was observed among users of HDACi AEDs (HR = 0.87, 95% CI = 0.76-1.01), but no risk difference was found when comparing HDACi AED users to users of other AEDs (HR = 0.98, 95% CI = 0.76-1.27). Our study showed a decrease in overall PCa risk among men using AEDs compared to nonusers. The risk associations were similar for HDAC inhibitors as for AEDs in general.
Subject: antiepileptic drugs
HDAC inhibition
prostate cancer
317 Pharmacy
3122 Cancers
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Intl_Journal_of ... sh_Randomized_Study_of.pdf 1.076Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record